Clp-targeting BacPROTACs impair mycobacterial proteostasis and survival
- PMID: 37137307
- DOI: 10.1016/j.cell.2023.04.009
Clp-targeting BacPROTACs impair mycobacterial proteostasis and survival
Abstract
The ClpC1:ClpP1P2 protease is a core component of the proteostasis system in mycobacteria. To improve the efficacy of antitubercular agents targeting the Clp protease, we characterized the mechanism of the antibiotics cyclomarin A and ecumicin. Quantitative proteomics revealed that the antibiotics cause massive proteome imbalances, including upregulation of two unannotated yet conserved stress response factors, ClpC2 and ClpC3. These proteins likely protect the Clp protease from excessive amounts of misfolded proteins or from cyclomarin A, which we show to mimic damaged proteins. To overcome the Clp security system, we developed a BacPROTAC that induces degradation of ClpC1 together with its ClpC2 caretaker. The dual Clp degrader, built from linked cyclomarin A heads, was highly efficient in killing pathogenic Mycobacterium tuberculosis, with >100-fold increased potency over the parent antibiotic. Together, our data reveal Clp scavenger proteins as important proteostasis safeguards and highlight the potential of BacPROTACs as future antibiotics.
Keywords: BacPROTAC; Clp protease; ClpC1; Mycobacterium tuberculosis; antibiotics; cyclomarin A; ecumicin; protein quality control; small-molecule degrader; targeted protein degradation.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests K.F., V.M.S., K.R., H.W., and G.B. were employees of Boehringer Ingelheim at the time of this work.
Comment in
-
BacPROTAC to treat tuberculosis.Nat Rev Drug Discov. 2023 Jun;22(6):448. doi: 10.1038/d41573-023-00073-1. Nat Rev Drug Discov. 2023. PMID: 37142699 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous